Oxford Cannabinoid Technologies Holdings Plc (OCTHF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oxford Cannabinoid Technologies Holdings Plc (OCTHF) trades at $0.0028. Oxford Cannabinoid Technologies Holdings Plc is a pharmaceutical company focused on developing cannabinoid-based prescription medicines. Market cap: $3.05M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for OCTHF: OCTHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OCTHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OCTHF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Oxford Cannabinoid Technologies Holdings Plc (OCTHF) Healthcare & Pipeline Overview
Oxford Cannabinoid Technologies Holdings Plc is a UK-based pharmaceutical company specializing in the research and development of cannabinoid-based prescription medicines, primarily targeting pain management through its pre-clinical drug candidates like OCT461201 and OCT130401, positioning it within the emerging biotechnology sector focused on cannabinoid therapeutics.
What Is the Investment Thesis for OCTHF?
Oxford Cannabinoid Technologies Holdings Plc presents a speculative investment opportunity within the emerging cannabinoid-based pharmaceutical sector. The company's value hinges on the successful development and commercialization of its pre-clinical drug candidates, OCT461201 and OCT130401. Key value drivers include positive pre-clinical trial results, successful navigation of regulatory pathways, and strategic partnerships for clinical development and commercialization. The current market capitalization of $3.05M reflects the early stage of the company and the inherent risks associated with drug development. Upcoming milestones include advancing OCT461201 and OCT130401 through further pre-clinical studies and initiating Phase 1 clinical trials. A significant risk factor is the high attrition rate in pharmaceutical development, particularly for novel therapies. The company's ability to secure funding for ongoing research and development is also critical for its long-term viability.
Based on FMP financials and quantitative analysis
OCTHF Key Highlights
Lead drug candidate OCT461201 is in pre-clinical development targeting IBS-associated visceral pain and neuropathic pain conditions.
- OCT130401 is in pre-clinical development for the treatment of trigeminal neuralgia.
- The company focuses on cannabinoid-based prescription medicines, a growing area of pharmaceutical research.
- Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017, indicating its relatively early stage of development.
- The company's P/E ratio is -0.19, reflecting its current lack of profitability.
Who Are OCTHF's Competitors?
OCTHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRRGF BerGenBio ASA | $97.09 | +0.00% | $9.49B | 74 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OCTHF's Key Strengths?
Focus on cannabinoid-based prescription medicines.
- Proprietary drug candidates in pre-clinical development.
- Potential for addressing unmet needs in pain management.
- Experienced management team.
What Are OCTHF's Weaknesses?
Early stage of development with no approved products.
- Reliance on external funding for research and development.
- Limited operating history.
- Small number of employees.
What Could Drive OCTHF Stock Higher?
Publication of pre-clinical trial results for OCT461201.
- Initiation of Phase 1 clinical trials for OCT461201.
- Progress in the development of OCT130401 for trigeminal neuralgia.
- Securing partnerships for clinical development and commercialization.
- Advancements in cannabinoid research and drug delivery technologies.
What Are the Key Risks for OCTHF?
Financial-distress signal — its Altman Z-Score of -28.57 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-86.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and uncertainties surrounding cannabinoid-based medicines.
- Competition from other pharmaceutical companies and cannabis producers.
- High attrition rate in pharmaceutical development.
- Adverse side effects or safety concerns associated with cannabinoid therapies.
- Reliance on external funding for research and development.
What Are the Growth Opportunities for OCTHF?
- Expansion into New Therapeutic Areas: Oxford Cannabinoid Technologies Holdings Plc has the opportunity to expand its pipeline beyond pain management to address other therapeutic areas where cannabinoids may have potential, such as epilepsy, multiple sclerosis, and anxiety disorders. This would require further research and development efforts, but could significantly broaden the company's market reach and revenue potential.
- Strategic Partnerships for Clinical Development: Collaborating with larger pharmaceutical companies or research institutions can accelerate the clinical development of OCT461201 and OCT130401. These partnerships can provide access to funding, expertise, and resources needed to conduct clinical trials and navigate the regulatory approval process. Successful partnerships could also enhance the company's credibility and attract further investment. Timeline for partnerships is ongoing.
- Geographic Expansion: While currently focused on the UK, Oxford Cannabinoid Technologies Holdings Plc can expand its operations to other countries with favorable regulatory environments for cannabinoid-based medicines, such as Canada, Germany, and Australia. This would involve establishing local subsidiaries or partnering with distributors to market and sell its products. The global market for medical cannabis is expected to continue growing rapidly, providing ample opportunities for geographic expansion. Timeline is dependent on regulatory approvals.
- Development of Novel Delivery Systems: Investing in the development of novel drug delivery systems, such as transdermal patches or inhaled formulations, can improve the bioavailability and efficacy of cannabinoid-based medicines. This could provide a competitive advantage over existing treatments and attract patients seeking more convenient or effective options. The market for advanced drug delivery systems is experiencing significant growth, driven by increasing demand for personalized medicine. Timeline is dependent on research and development.
- Intellectual Property Protection: Strengthening its intellectual property portfolio through patents and trademarks can protect Oxford Cannabinoid Technologies Holdings Plc's proprietary technologies and drug candidates from competition. This would involve filing patent applications for novel cannabinoid formulations, drug delivery systems, and methods of treatment. A strong IP portfolio can also increase the company's attractiveness to potential acquirers or partners. Timeline is ongoing.
What Are OCTHF's Competitive Advantages?
- Proprietary cannabinoid-based drug candidates.
- Focus on prescription medicines with potential for patent protection.
- Expertise in cannabinoid research and development.
- Potential for first-mover advantage in specific therapeutic areas.
What Does OCTHF Do?
Oxford Cannabinoid Technologies Holdings Plc, incorporated in 2017 and headquartered in London, is a pharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-based prescription medicines. The company's primary focus is on addressing unmet needs in pain management through innovative cannabinoid therapies. Their lead drug candidate, OCT461201, is a selective CB2 receptor agonist formulated as a solid oral dosage. Currently in pre-clinical development, OCT461201 is being investigated for the treatment of IBS-associated visceral pain and various neuropathic pain conditions, including post-herpetic neuralgia. Another key asset in their pipeline is OCT130401, also in pre-clinical development, targeting trigeminal neuralgia. The company aims to leverage the therapeutic potential of cannabinoids to create novel prescription medicines that offer improved efficacy and safety profiles compared to existing treatments. Oxford Cannabinoid Technologies Holdings Plc operates primarily in the United Kingdom, focusing its research and development efforts on advancing its pipeline of cannabinoid-based therapeutics through the various stages of drug development, with the ultimate goal of bringing innovative medicines to market.
What Products and Services Does OCTHF Offer?
- Researches and develops cannabinoid-based prescription medicines.
- Focuses on treatments for pain management, including IBS-associated visceral pain and neuropathic pain.
- Develops selective CB2 receptor agonists.
- Conducts pre-clinical studies for its drug candidates.
- Aims to commercialize its cannabinoid-based therapies.
- Develops solid oral dosage forms for its medications.
How Does OCTHF Make Money?
- Develops cannabinoid-based drug candidates.
- Out-licenses or partners with other pharmaceutical companies for clinical trials and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Focuses on prescription medicines rather than recreational cannabis products.
What Industry Does OCTHF Operate In?
Oxford Cannabinoid Technologies Holdings Plc operates within the biotechnology industry, specifically targeting the emerging market for cannabinoid-based therapeutics. This market is driven by increasing acceptance of medical cannabis and ongoing research into the therapeutic potential of cannabinoids. The competitive landscape includes companies like ATIP, AWKNF, BRRGF, CIMVF, and DLTNF, which are also exploring cannabinoid-based treatments. The overall biotechnology industry is experiencing growth, fueled by advancements in drug discovery and increasing investment in research and development. However, the cannabinoid therapeutics market is still relatively nascent, with regulatory uncertainties and evolving consumer perceptions.
Who Are OCTHF's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel drug candidates.
- Patients suffering from chronic pain conditions.
- Healthcare providers prescribing pain management medications.
- Potential partners for clinical trials and commercialization.
Company Profile
Oxford Cannabinoid Technologies Holdings Plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Clarissa Ann Sowemimo-Coker. OCTHF has traded publicly since 2021.
How Oxford Cannabinoid Technologies Holdings Plc Is Valued
Oxford Cannabinoid Technologies Holdings Plc carries a market capitalization of $3.05M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Oxford Cannabinoid Technologies Holdings Plc stands at -86.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 7.69 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Oxford Cannabinoid Technologies Holdings Plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.57 places it in the distress zone, a signal of elevated financial risk.
OCTHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on cannabinoid-based prescription medicines.
- Proprietary drug candidates in pre-clinical development.
- Potential for addressing unmet needs in pain management.
- Experienced management team.
Bear Case
- Early stage of development with no approved products.
- Reliance on external funding for research and development.
- Limited operating history.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
OCTHF Latest News
No recent news available for OCTHF.
OCTHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OCTHF.
Price Targets
Wall Street price target analysis for OCTHF.
OCTHF MoonshotScore
What does this score mean?
The MoonshotScore rates OCTHF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Clarissa Ann Sowemimo-Coker
CEO
Clarissa Ann Sowemimo-Coker is the CEO of Oxford Cannabinoid Technologies Holdings Plc. Her background includes experience in the pharmaceutical and biotechnology industries. She is responsible for leading the company's strategic direction, overseeing research and development activities, and managing the company's operations. She manages a small team of 5 employees, reflecting the company's early stage of development. Additional details regarding her specific career history and educational background are not available.
Track Record: Due to the limited information available, it is difficult to assess Clarissa Ann Sowemimo-Coker's track record at Oxford Cannabinoid Technologies Holdings Plc. The company is still in its early stages of development, with no approved products currently on the market. Her leadership will be crucial in guiding the company through the clinical development and regulatory approval processes.
OCTHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Oxford Cannabinoid Technologies Holdings Plc may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing standards, potentially increasing investment risk.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in OCTHF.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- OTC Other companies may be subject to less regulatory oversight.
- The lack of stringent listing standards increases the risk of fraud or mismanagement.
- Potential for delisting or suspension of trading due to non-compliance with OTC requirements.
- Verify the company's financial statements and disclosures, if available.
- Research the company's management team and their experience.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company is incorporated in the United Kingdom, a jurisdiction with established corporate governance standards.
- Oxford Cannabinoid Technologies Holdings Plc has a clearly defined business model focused on pharmaceutical research and development.
- The company is focused on developing prescription medicines, suggesting a commitment to scientific rigor and regulatory compliance.
- The company has a CEO, Clarissa Ann Sowemimo-Coker, indicating a formal management structure.
- The company's focus on cannabinoid-based therapies aligns with a growing area of pharmaceutical research.
Common Questions About OCTHF (Healthcare)
What does Oxford Cannabinoid Technologies Holdings Plc do?
Oxford Cannabinoid Technologies Holdings Plc is a pharmaceutical company focused on the research, development, and potential commercialization of cannabinoid-based prescription medicines. Their primary focus is on developing treatments for pain management, with their lead drug candidate, OCT461201, targeting IBS-associated visceral pain and neuropathic pain conditions.
What do analysts say about OCTHF stock?
As of 2026-03-17, there is no available analyst coverage for Oxford Cannabinoid Technologies Holdings Plc (OCTHF). This is likely due to the company's small market capitalization of $3.05M and its listing on the OTC Other market. The lack of analyst coverage makes it difficult to assess the stock's valuation and potential upside.
What are the main risks for OCTHF?
Oxford Cannabinoid Technologies Holdings Plc faces several significant risks typical of a pre-clinical stage pharmaceutical company operating in the cannabinoid space. A primary risk is the uncertainty inherent in drug development; OCT461201 and OCT130401 may not prove safe or effective in clinical trials.
What are the key factors to evaluate for OCTHF?
Evaluate OCTHF on fundamentals, analyst consensus, and risk factors. Oxford Cannabinoid Technologies Holdings Plc presents a speculative investment opportunity within the emerging cannabinoid-based pharmaceutical sector. Not financial advice.
How frequently does OCTHF data refresh on this page?
OCTHF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OCTHF's recent stock price performance?
Oxford Cannabinoid Technologies Holdings Plc (OCTHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabinoid-based prescription medicines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OCTHF overvalued or undervalued right now?
Oxford Cannabinoid Technologies Holdings Plc (OCTHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OCTHF before investing?
Before investing in Oxford Cannabinoid Technologies Holdings Plc (OCTHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC Other stocks are inherently riskier than those listed on major exchanges.
- Analyst coverage is non-existent.